Dickkopf-1 as a promising therapeutic target for autoimmune diseases

Sha-Sha Tao; Fan Cao; Napoleon Bellua Sam; Hong-Miao Li; Ya-Ting Feng; Jing Ni; Peng Wang; Xiao-Mei Li; Hai-Feng Pan

doi:10.1016/j.clim.2022.109156

Dickkopf-1 as a promising therapeutic target for autoimmune diseases

Clin Immunol. 2022 Dec:245:109156. doi: 10.1016/j.clim.2022.109156. Epub 2022 Oct 17.

Authors

Sha-Sha Tao¹, Fan Cao², Napoleon Bellua Sam³, Hong-Miao Li⁴, Ya-Ting Feng⁴, Jing Ni⁴, Peng Wang⁵, Xiao-Mei Li⁶, Hai-Feng Pan⁷

Affiliations

¹ Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Preventive Medicine Experimental Teaching Center, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China. Electronic address: taoshasha@1212.126.com.
² Department of Ophthalmology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, China.
³ School of Medicine, University for Development Studies, Tamale, N/R, Ghana.
⁴ Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.
⁵ Teaching Center for Preventive Medicine, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei 230032, Anhui, China.
⁶ School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China; The First Affiliated Hospital of USTC, Department of Rheumatology and Immunology, University of Science and Technology of China, No 17 Lujiang Road, Hefei, China.. Electronic address: lixiaomei@ustc.edu.cn.
⁷ Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China. Electronic address: panhaifeng1982@sina.com.

PMID: 36257529
DOI: 10.1016/j.clim.2022.109156

Abstract

Dickkopf-1 (DKK-1) is mostly known as a mature inhibitor of classic Wnt signaling pathways, which plays a critically role in regulating bone formation and bone metastasis. In recent years, the roles of DKK-1 played in bone resorption, bone formation, immune homeostasis and inflammation have been investigated. The role of DKK-1 in the pathogenesis and treatment of autoimmune diseases (ADs), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), etc, has attracted widespread attention. Various studies have found that DKK-1 may be used as a biomarker for the occurrence and development of ADs, and as a potential target for the treatment of ADs. In this review, we have briefly summed up the intricate immunological functions and regulatory mechanisms of DKK-1 in ADs, aiming to further learning more about the role of DKK-1 involved in the pathogenesis of ADs and provide an outlook for the potential future researches.

Keywords: Autoimmune diseases; Biomarker; DKK-1; Therapeutic target.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Rheumatoid* / drug therapy
Autoimmune Diseases* / drug therapy
Bone Resorption*
Humans
Intercellular Signaling Peptides and Proteins
Lupus Erythematosus, Systemic* / drug therapy

Substances

Intercellular Signaling Peptides and Proteins